October 6th, 2022, 10:00-11:30 am ET / 4:00-5:30 pm CDT
Overview
In the management of non-small cell lung cancer, targeted therapies directed against proteins involved in oncogenesis and disease progression have revolutionized treatment, improving outcomes for select patients. Recent research efforts have been focused on the discovery and exploitation of novel therapeutic targets, with the goal of expanding the reach of effective targeted therapy.
In this live webcast, experts in the management of NSCLC will discuss current and emerging treatment approaches for novel cell surface targets. This includes insights into treatment options currently in development, focusing of efficacy and safety data, with the goal of explaining how these agents may impact on the treatment landscape of NSCLC in the future. These concepts will be illustrated by challenging case presentations detailing the potential benefit of emerging treatment options directed against cell surface proteins.
Benefits of Attending
- Engage leading researchers in the development of novel targeted therapies for NSCLC
- Learn how recent data from major lung cancer meetings will impact treatment for patients
- Bring your burning questions about emerging targeted therapies in NSCLC
Target Audience
This educational activity is directed toward a global audience of community and academic medical oncologists, pathologists, molecular pathologists, thoracic surgeons, NPs/PAs, pharmacists, and nurses.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Assess the mechanistic rationales for targeting HER2-, HER3-, and TROP2 to treat advanced NSCLC
- Determine key evidence from trials that have evaluated the efficacy and safety of HER2-, HER3-, and TROP2-targeted approaches to manage patients with advanced NSCLC
- Explain how recent findings from investigations on therapies targeting HER2, HER3, and TROP2 pathways should be considered in the context of evolving treatment paradigms in advanced NSCLC.
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC |
||
10:00 – 10:05 AM |
Welcome and Introductions |
Edward Garon |
10:05 – 10:25 AM |
Evolving Roles of HER2 in Advanced NSCLC: Molecular Testing Implications and Advent of Treatment Advances |
Jacob Sands |
10:25 – 10:40 AM |
Critical Clinical Updates from Recent Society Meetings and Beyond Regarding HER2, HER3, and TROP2 Targeted Approaches in Advanced NSCLC |
Edward Garon |
10:40 – 11:00 AM |
Show Me the Data Case 1: Treatment Strategies for a patient with NSCLC and documented HER2 positivity |
Solange Peters |
11:00 – 11:20 AM |
Show Me the Data Case 2: Treatment strategies for a patient with NSCLC progressing after EGFR targeted therapy. |
Rebecca Heist |
11:20 – 11:30 AM |
Concluding Remarks/Adjourn |
Edward Garon |
Edward B. Garon, MD, MS
Professor of Medicine (Hematology/Oncology)
David Geffen School of Medicine at the University of California, Los Angeles
Los Angeles, CA
Rebecca Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Solange Peters, MD, PhD
Professor of Medicine
Chair, Thoracic Malignancies
Head, Medical Oncology
Oncology Department
Lausanne University Hospital
Lausanne, Switzerland
Jacob Sands, MD
Physician
Dana-Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Boston, MA
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.